Best Binary Options Broker 2020!
Perfect For Beginners!
Free Demo Account!
Free Trading Education!
Get Your Sign-Up Bonus Now!
Good Choice For Experienced Traders! 2nd place in the ranking!
Nifty Technical Analysis
Nail The Profitability Equation Today
Get DTF Membership Now
Get Inatant Access to all Premium Content for 3 Months!
Still, using Traditional Technical Analysis Tools with Poor Trading Results?
Stop today and learn how our framework will change the way you look at markets forever…
We use advanced technical tools to analyse the markets. But the real magic happens with the underlying philosophies that provide deeper insights.
Underlying Core Philosophies that guide us in our trading…
These core philosophies provide unparalleled insights into the markets and help you make the most prudent trading decisions…
Market Profile – Best tool to convert “market understanding” into “trading opportunities”…
We absolutely love Market Profile. Once you become good at it markets will talk to you like they never did before…
Volume Spread Analysis – There is no other tool which combines “context” with “timing” as well…
A single VSA chart has the power to become a complete trading system for you, right from finding trades to executing them…
Order Flow Analysis – When it comes to timing your trades there is nothing better than OFA charts…
In the hands of a novice though this tool can cause more harm than good. Luckily we have covered it in great detail so that it becomes your best weapon for timing your trades…
Why you should join Dean Trading Framework Membership?
There are many reasons why you should become a part of the DTF Members. Only a few pertinent ones are shared below…
Get DTF Membership Now
Get Inatant Access to all Premium Content for 3 Months!
What path you will follow after you join Dean Trading Framework Quarterly Membership?
We have ensured that your learning goes as smoothly as possible. That is why we advise you to follow the sequence below when you are consuming content offered in DTF Membership…
Join DTF Quarterly Membership
We have purposefully kept the renewals quarterly so you dont have to renew it often. Also, you get sufficient time to study the content on the website.
Best Binary Options Broker 2020!
Perfect For Beginners!
Free Demo Account!
Free Trading Education!
Get Your Sign-Up Bonus Now!
Good Choice For Experienced Traders! 2nd place in the ranking!
Learning Phase 1: Advanced Technical Analysis Course
In this course you will learn all about the underlying philosophies we use to make sense of the amrkets. This is probably the most important section, and no trader, whether beginner or experience should ever skip this.
Learning Phase 2: Market Profile Course
In this course you will learn the best tool to apply the core philosophies to real-time markets. You will learn how to understand the all important context.
Leraning Phase 3: Volume Spread Analysis Course
Inthis course you will learn how to apply the VSA system and the tweaks and modifications we have done to it in DTF. This one tool is powerful enough to form a complete trading system in itself.
Learning Phase 4: Order Flow Course
In this course you will learn arguably the best timing tool avalable in the present times. We will learn this topoic in detail from basics to advanced application.
Learning Phase 5: Live Market Sessions
Now we will be conducting live sessions twice a week. So you can see how we analyse the market using these tools and principles. (No trading recomendations at all.) But not only that we have recorded all our live sessions during the Intensive and you can go through them one by one for practical application of these tools.
Learning Phase 6: Continuous Interaction
We are giving you access to member only Telegram Group and Facebook Group. So you can stay in touch with us all the time. Please understand the more questions you ask and feedback you provide the better this course and membership will become.
Join The Dean Trading Framework Membership NOW!
And begin your journey towards consistent trading profitability…
Get INSTANT Access to ALL Premium Content
We Get These Questions A Lot
These are common questions we get asked a lot. So we made a list for you so you can refer to them easily…
Yes absolutely. You can stay in touch with us on member-only Telegram and Facebook group. You can chat with us on messenger right from this website. Or you can send us an old fashioned email on [email protected]
You get instant access to all the content on our website. Any content we add during your active membership will be available to you instantly.
To answer all your queries and doubts we are planning to conduct Live Market Sessions (twice a week Mondays and Thursdays) and a member-only QnA Session every fortnight (on Saturdays). The recordings of these sessions will be available too.
This is important. You will have complete unrestricted access to all the content on the website only till you have an active membership. The moment your membership expires, you access to all the content on the website will expire too. In short to access the content on the website you need to have an active membership all the time.
We have made every effort to make the content useful and practical. But if you don’t like it you can stop your membership anytime. But since we have made full commitment to bring you the best content possible and have plans to keep adding more and more, we want you to make the same commitment to learning. That is why the minimum you can do is join us for 3 months. Beyond that, it is up to you. Hence no refunds shall be issued under any circumstances. If you decide to join us with a minimum commitment of 3 months.
Part 24: Technical Analysis – Fibonacci Sequence
CLONOSEQ ® ASSAY TECHNICAL INFORMATION
The clonoSEQ Assay is an in vitro diagnostic that uses multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) to identify and quantify rearranged IgH (VDJ), IgH (DJ), IgK, and IgL receptor gene sequences, as well as translocated BCL1/IgH (J) and BCL2/IgH (J) sequences in DNA extracted from bone marrow from patients with B-Cell acute lymphoblastic leukemia (ALL) or multiple myeloma (MM).
The clonoSEQ Assay measures minimal residual disease (MRD) to monitor changes in burden of disease during and after treatment. The test is indicated for use by qualified healthcare professionals in accordance with professional guidelines for clinical decision-making and in conjunction with other clinicopathological features.
The clonoSEQ Assay is a single-site assay performed at Adaptive Biotechnologies Corporation.
There are no known contraindications.
SPECIAL CONDITIONS FOR USE
- For in vitro diagnostic use.
- For prescription use only (Rx only).
SUMMARY AND EXPLANATION
The clonoSEQ Assay is an in vitro diagnostic assay that utilizes NGS to identify frequency and distribution of clonal sequences consistent with a malignant lymphocyte population in a sample.
Minimal Residual Disease (MRD) refers to the number of cancer cells that remain in a person during and following treatment. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcome and response to therapy. Studies in hematological malignancies have demonstrated the strong correlation between MRD and risks for relapse, as well as the prognostic significance of MRD measurements during and after therapy. In acute lymphoblastic leukemia MRD assessment has been established as an essential component in clinical management and is recommended to occur upon completion of initial induction and at additional time points based on the regimen used. 3
In multiple myeloma MRD assessment after each treatment stage is recommended (e.g., after induction, high-dose therapy/ASCT, consolidation, maintenance). MRD tests may also be initiated at the time of suspected complete response. 4
- MRD values obtained with different assay methods may not be interchangeable due to differences in assay methods and reagent specificity.
- The results obtained from this assay should always be used in combination with the clinical examination, patient medical history, and other findings.
- The clonoSEQ Assay is for use with bone marrow specimens collected in EDTA tubes.
- Results may vary according to sample time within the course of disease or by sampling site location.
- The assay may overestimate MRD frequencies near the limit of detection (LoD).
- The MRD frequency LoD varies based on the amount of DNA that is tested and using lower DNA input may prevent MRD detection at low frequencies.
- Sample processing and cell enrichment strategies may affect the measured MRD frequency.
- The volume and cellularity of sampled input material may affect the ability to detect low levels of disease.
- False positive or false negative results may occur for reasons including, but not limited to: contamination; technical and/or biological factors.
The clonoSEQ Assay is a next-generation sequencing (NGS) based assay that identifies rearranged IgH (VDJ), IgH (DJ), IgK, and IgL receptor gene sequences, as well as translocated BCL1/IgH (J) and BCL2/IgH (J) sequences. The assay also includes primers that amplify specific genomic regions present as diploid copies in normal genomic DNA (gDNA) to allow determination of total nucleated cell content.
Testing begins with gDNA extracted from bone marrow (Figure 1). Extracted gDNA quality is assessed and rearranged immune receptors are amplified using a multiplex PCR. Reaction-specific index barcode sequences for sample identification are added to the amplified receptor sequences by PCR. Sequencing libraries are prepared from barcoded amplified DNA, which are then sequenced by synthesis using NGS. Raw sequence data are uploaded from the sequencing instrument to the Adaptive analysis pipeline. These sequence data are analyzed in a multi-step process: first, a sample’s sequence data are identified using the sample index sequences. Next, data are processed using a proprietary algorithm with in-line controls to remove amplification bias. When the clonoSEQ Clonality (ID) assessment is conducted, the immune repertoire of the sample is checked for the presence of DNA sequences specific to “dominant” clone(s) consistent with the presence of a lymphoid malignancy. Each sequence that is being considered for MRD tracking is compared against a B cell repertoire database and assigned a uniqueness value that, together with its abundance relative to other sequences, is used to assign the sequence to a sensitivity bin which will be used in the estimation of the reported LoD and LoQ on the patient report. During clonoSEQ Tracking (MRD) assessment, the complete immunoglobulin receptor repertoire is again assessed, and the previously identified dominant clonotype sequence(s) are detected and quantified to determine the sample MRD level. The clonoSEQ assay MRD assessment measures residual disease in a biologic sample.
Figure 1: clonoSEQ Assay Workflow
Following completion of these data processing steps, a report is issued. A Clonality (ID) report indicates the presence of dominant sequences residing within a presumed malignant lymphocyte clonal population, as identified in the baseline (diagnostic or high disease burden) sample from a patient. After one or more dominant sequence(s) have been identified in a baseline sample, subsequent samples from the same patient can be assessed for MRD after which a Tracking (MRD) report is generated. The MRD is expressed as a frequency that quantifies the level of residual disease based on the number of remaining copies of the initially dominant sequence(s) relative to the total number of nucleated cells in the sample.
The minimum DNA sample input requirement is 500ng. Shipment of 1ml of bone marrow aspirate (BMA) is requested to obtain sufficient extracted gDNA and extraction methods have been validated using volume ranging from 250 µL to 1 mL. The extraction method isolates DNA by first lysing cells and denaturing proteins after which the DNA is bound to a substrate. Once the DNA is bound, a series of wash steps removes impurities. Following the wash steps the DNA is eluted from the substrate. DNA is quantified using a spectrophotometer; the measured DNA concentration is used to add up to 20 µg of gDNA to the assay. The MRD test can be performed with 500 ng – 20 µg gDNA. Internal controls in the PCR and sequencing steps are used to confirm that sufficient gDNA has been amplified and that amplification was successful.
Genomic DNA is amplified using locus-specific multiplex PCR using V, D and J gene primers containing molecular barcodes to amplify IgH (VDJ), IgH (DJ), IgK, IgL, BCL1/IgH (J), BCL2/IgH (J) and housekeeping gene (HKG) sequences. Reaction-specific index barcodes for sample identification are added to the amplified receptor sequences by PCR. Sequencing libraries are prepared by pooling barcoded amplified DNA. qPCR is used to verify the adequacy of the pooled amplified DNA library concentration.
Sequencing and Data Analysis
Sequencing is conducted with the Illumina NextSeq TM 500 System. The sequencing process incorporates multiple quality checks. Sequencing output is then processed by the bioinformatics pipeline software as follows:
Flowcell Level Metrics
The analysis pipeline performs quality control (QC) checks on the flowcell data. The pipeline evaluates the percentage of reads that pass the Illumina quality filter (%PF), which must be greater than 70% of reads. The system uses spike-in PhiX templates to evaluate the error rate. The pipeline evaluates the proportion of PhiX reads, which must be greater than 2%, and the associated error rate as computed by the Illumina RTA software, which must be less than 3%.
Demultiplexing and FASTQ Generation
The pipeline uses Illumina software to demultiplex reads from the instrument output run folder. The analysis pipeline performs a QC check to evaluate whether unexpected barcodes are observed and raises a flag if more than 30,000 reads carry a barcode not specified in the input sample sheet.
Read Assignment to Receptors
The pipeline assigns reads to rearranged receptors for each sample after demultiplexing.
Clonal Sequence Determination
After assigning reads to receptor loci, the pipeline then clusters reads into clonal receptor sequences.
Sample Level QC Checks
The pipeline performs a series of sample level QC checks: assessment that sequencing data is sufficient and acceptable based on amplification of sets of internal synthetic controls, assessment that sufficient gDNA is sampled, and a final screen of the calculated values for biologic relevance. One set of internal synthetic controls are evaluated for sufficient read quantity per molecule and read coverage across receptor loci. Another set of internal controls’ presence or absence is used to screen for the expected degradation of residual primers. The estimated mass of input gDNA based on an optical density measurement and the estimated number of sampled nucleated cells based on amplification of a set of internal reference gene are used as metrics to check if sufficient material is sampled. The pipeline also checks that the detected numbers of total and B cells are within a biologically relevant range, and screens for clone sharing by evaluating if sequences are shared across samples that are processed together.
Clonal sequences are assessed for their suitability as ID sequences (to be used for subsequent tracking) by first aggregating highly similar sequences and requiring that the frequency of the sequence is at least 3% as a percentage of all sequences in the locus. The clone must also have a frequency of at least 0.2% of all nucleated cells in the sample and must have sufficient abundance and differentiation from a polyclonal background. Each sequence that is being considered for MRD tracking is compared against a B cell repertoire database and assigned a uniqueness value that, together with its abundance relative to other sequences, is used to assign the sequence to a sensitivity bin which will be used in the estimation of the reported limit of detection (LoD) and limit of quantitation (LoQ).
When a previous calibration test has identified suitable ID sequences for tracking, they are compared to sequences in the most recent tracking sample in order to assess residual disease. After approximate matching, which allows for mutations in the sample clones as compared to the ID sequences, sequence proportions in the sample are assessed and compared to the LoD and LoQ values. The analysis pipeline then reports whether ID sequences were detected above the LoQ, above LoD but below LoQ, below LoD, or not detected.
The following controls are used to measure the success of DNA extraction, PCR amplification and sequencing:
Synthetic Internal Controls
Each sample includes two sets of internal synthetic controls. The controls are panels of synthetic analogues of somatically rearranged B-cell receptor (BCR) immune receptor molecules. The composition of the reference template pools before and after amplification is measured and used for QC. One set of synthetic templates is added to every pre-amp PCR well as a positive control; these synthetic templates are used to measure primer performance, including identification and correction of amplification bias, and to screen for sufficient sequencing coverage. Another set is added after a step used to remove residual primers; the lack of amplification of these molecules is used to confirm the success of primer removal.
DNA Extraction Process Controls
Each extraction is performed with Positive and Negative Extraction Controls. The Extraction Negative Control is used to confirm lack of contamination during the extraction process. The Extraction Negative Control is subsequently amplified and sequenced in the same fashion as test samples. The Extraction Positive Control is included to assess effectiveness of the extraction process (it is required to be above a pre-set threshold for DNA recovery). If readily available, source material for Extraction Positive Controls is matched to the specimen source type. Exception: The Extraction Positive Control for bone marrow specimens consists of frozen human whole blood.
PCR Amplification Process Controls
Each PCR amplification is performed with an Amplification Positive and Negative Control and subsequently sequenced in the same manner as test samples. The Amplification Positive Control consists of gDNA derived from peripheral blood mononuclear cells (PBMCs) and serves as an additional check to confirm successful product amplification. Buffer (1xTE) is used as the negative control.
Sequencing Process Controls
To every sequencing flow cell, two sequencing controls are added. Both a PhiX control purchased from Illumina and a well-characterized amplified library (Sequencing Positive Control) are loaded with test samples.
The pipeline renders results into a PDF-formatted patient report. The report displays any ID sequences identified in the sample that can be used for tracking with their quantitation and sample-level metrics. For tracking tests, the report includes a result (ID sequences detected above LoD, below LoD, or not detected) and quantitation for the tracked sequences within the most recent sample.
Standards/Guidance Documents Referenced
CLSI guideline EP06-A Evaluation of the Linearity of Quantitative Measurement Procedures- A Statistical Approach.
All reagents, materials, and equipment needed to perform the assay, with the exception of sample collection materials, are used exclusively at the Adaptive Biotechnologies single laboratory site. The clonoSEQ Assay is intended to be performed with serial number-controlled instruments.
An ambient temperature sample shipper kit is optional for use and is available through Adaptive Clinical Services Team if requested by the ordering healthcare provider.
SAMPLE COLLECTION AND TEST ORDERING
For clonoSEQ sample collection requirements and ordering information please visit: www.adaptivebiotech.com/clonoseq/ordering
The clonoSEQ Assay is intended to be performed using the:
- Illumina NextSeq TM 500 Series System (qualified by Adaptive Biotechnologies)
2. PERFORMANCE CHARACTERISTICS
2.1 Sample Stability
2.1.1 Frozen Bone Marrow Stability at -15° C to -25° C
To demonstrate frozen bone marrow stability, four bone marrow samples from donors were aliquoted and stored frozen (-15° C to -25° C). Samples were tested after freezing and the frequencies of predefined clones within the specimen were compared to baseline. Frozen bone marrow was stable for 12 months at -15°C to -25°C based on all tested clone frequencies in all samples being within the prespecified ± 30% MRD frequency variation.
2.1.2 Bone Marrow Stability at Room Temperature and Refrigerated
To demonstrate bone marrow stability, four bone marrow samples from donors were aliquoted and stored at room temperature (19° C to 25° C) or refrigerated (2° C to 8° C) for up to seven days.
Bone marrow samples stored at room temperature (19° C to 25° C), remained stable for three days as established by MRD measurements remaining within the allowable ± 30%. For bone marrow samples stored refrigerated (2° C to 8° C), MRD measurements remained within the prespecified ± 30% frequency variation for at least seven days establishing seven days of stability.
2.1.3 Shipping Stability
Sample stability of bone marrow samples stored in Adaptive shipping containers at ambient temperature was tested after exposure to simulated summer and winter shipping conditions. Study results demonstrated that samples are stable for up to 4 days (96 hours), based on MRD frequencies remaining equivalent within the prespecified ± 30% under ambient shipping conditions.
2.1.4 Freeze/Thaw Stability of Bone Marrow Samples
The stability of bone marrow samples was evaluated using four bone marrow samples from donors split into aliquots (0.25ml) with one aliquot extracted upon receipt. The remaining aliquots were subjected to freeze/thaw cycles. gDNA was extracted and the concentration was determined using a spectrophotometer. Each sample was processed using the clonoSEQ Assay. Bone marrow samples subjected to three freeze/thaw cycles continued to report acceptable sample MRD frequencies remaining within the prespecified ± 30%.
2.2 Specimen Characterization
A panel of clinical specimens from 23 patients with MM and 21 patients with ALL was used for precision, quantitation accuracy and linearity studies. An additional 22 specimens from patients with other lymphoid malignancies were used to supplement the analytical sensitivity studies. Sample types included bone marrow (BMA), BMMCs, CD138+ bone marrow cells, peripheral blood, and PBMCs. gDNA was isolated from these clinical samples and blended with gDNA isolated from bone marrow to contrive specific MRD levels for the analytical studies.
A study was performed to evaluate whether MRD estimates from blended gDNA were equivalent to MRD estimates from blended cells at known concentrations. The accuracy and linearity of sample MRD frequency was assessed at zero and across 11 MRD frequency levels ranging from 3.3×10 -7 to 3.0×10 -3 for both blended gDNA and DNA extracted from blended cells. These dilutions included levels below LoD and spanned the range of reportable MRD levels. The MRD estimates on gDNA blends were comparable to the MRD estimates of the blended cells they were intended to mimic. Therefore, the blended gDNA from the clinical samples were determined to be functionally equivalent to clinical specimens for use in specific analytical studies.
Methods to isolate gDNA from BMA, bone marrow mononuclear cells (BMMCs), formalin fixed paraffin embedded (FFPE) bone marrow clot slides, and BMA smear slides were evaluated for performance in the clonoSEQ Assay. Studies were performed to determine extraction equivalence across four extraction runs with three variables (automated extraction instrument, operator, and reagent lot). Based on the results of all extractions, the tested gDNA extraction variables (operator, instrument, extraction reagent lot, and extraction run) met acceptance criteria. DNA isolated from FFPE bone marrow clot slides and BMA smear slides was only assessed for utility in identifying sequences and not MRD tracking.
Precision studies tested gDNA extracted from clinical specimens from 23 patients with MM and 21 patients with ALL. The gDNA from these specimens were used to contrive specific MRD levels by pooling and blending them into gDNA extracted from the BMA of healthy donors. The study included three DNA inputs (500 ng, 2 μg, 20 μg) and six MRD levels were tested at each DNA input for each patient sample. The studies were designed to test the MRD levels of 2.8×10 -5 , 8.0×10 -5 , 2.8×10 -4 , 8.0×10 -4 , 2.8×10 -3 and 8.0×10 -3 at 500 ng DNA input; 7.0×10 -6 , 2.0×10 -5 , 7.0×10 -5 , 2.0×10 -4 , 7.0×10 -4 and 2.0×10 -3 at 2 µg DNA input; and 7.0×10 -7 , 2.0×10 -6 , 7.0×10 -6 , 2.0×10 -5 , 7.0×10 -5 and 2.0×10 -4 at 20 µg DNA input. These frequencies correspond to an estimated 2.14, 6.13, 21.44, 61.26, 214.40 and 612.56 malignant cells tested at each DNA dilution.
The precision study used a main effects screening design over 21 calendar days. This study used ten runs, with two PCR plates each run, using three operator sets, four reagent lots, and four instrument sets (two thermal cycler/liquid handlers and two NextSeq TM instruments). The study design is summarized in Figure 2.
Figure 2: Precision Study Design Schematic
Each run of the assay tested 18 combinations of DNA input and MRD frequency in duplicate. In all, 360 contrived samples were tested. Of these, one plate with 18 samples was invalid due to sample QC failures; the plate-level failure rate was therefore 1 / 20 = 0.05. An additional two contrived samples (88 MRD measurements) failed sample QC due to insufficient sequencing coverage. While normal operating procedures permit re-sequencing, for this analysis these two samples were classified as failures. The analysis used the remaining 340 contrived samples with up to 44 MRD measurements per sample, for a total of 14,744 MRD measurements.
The precision of the clonoSEQ Assay is largely dependent upon the number of malignant cells that are being evaluated rather than the MRD frequency. Consequently, the same MRD frequency is expected to have lower precision at lower DNA inputs. For this study, precision estimates were first calculated based on the MRD frequency per DNA input followed by estimates of imprecision of the absolute number of malignant cells detected per reaction.
Precision of MRD Frequency for MM and ALL
Precision analysis, including variation from instrument set, operator, processing day, processing run, and reagent lot, is reported as %CV for each tested MRD frequency at each DNA input. The analysis was done separately for MM and ALL and is summarized in Tables 1 and 2. Precision ranged from 29.6% to 70.0% CV for MM and 25.9% to 76.9% CV for ALL.
In these tables, MRD frequency range refers to the central 95% range of MRD estimates that were observed across all of the patient samples tested at each DNA input and frequency condition. These data were used to define the 95% confidence intervals that are used in patient reports.
Table 1: Precision of the clonoSEQ Assay in MM Samples
Note: Some contrived samples included a subset of patient samples.
Table 2: Precision of the clonoSEQ Assay in ALL Samples
Precision of Malignant Cells Detected
The precision of malignant cells detected was evaluated across the range of tested malignant cells (2.14 – 612.56). For this analysis, the results from all of the DNA inputs across MM and ALL were pooled into a single analysis that is summarized in Table 3. As expected, the precision was primarily influenced by cell numbers being evaluated. Precision ranged from 72% CV at 2.14 cells to 19% CV at 612.56 cells. The majority of the observed variation is due to residual variability; the tested factors (Operator, Instrument Sets, Reagent Lots, Day, and Run) minimally contributed to variability with attributable %CV ranging from 0% to 3% (Table 3).
Table 3: Summary of the clonoSEQ Assay Precision
* These values were aggregated across diseases (ALL and MM) and total DNA input levels
The precision for each sample at each tested condition across all DNA inputs is summarized in a Sadler’s precision profile (Figure 3). The Sadler’s precision profile visualizes the relationship between the number of sampled malignant cells and precision as measured by %CV. This analysis demonstrates that the precision of the clonoSEQ Assay is largely dependent on the number of malignant cells that are being evaluated by the assay.
Figure 3: Sadler’s Precision Profile (Coefficient of Variation) of the clonoSEQ Assay as a Function of Input Cancer Cells
2.5 Analytical Sensitivity
2.5.1 Limit of Blank
The LoB was determined by measuring the specificity of a patient’s trackable immunoglobulin (Ig) sequences. These sequences were identified from 66 samples from patients diagnosed with a lymphoid malignancy (23 MM, 21 ALL, and 22 other malignancy). The LoB was determined by searching for the presence and abundance of these trackable sequences in healthy bone marrow samples. The 95th percentile of sample MRD frequencies for these trackable sequences was zero at 500 ng and 20 μg gDNA input. Therefore, the LoB was zero, demonstrating that trackable Ig sequences are highly patient-specific.
2.5.2 Limit of Detection/Limit of Quantitation
The LoD and LoQ were determined by blending gDNA extracted from 66 specimens from patients with lymphoid malignancies (23 MM, 21 ALL, and 22 with other malignancy) into 500 ng and 20 μg of gDNA from bone marrow. A dilution series of 22.97, 10.72, 4.59, 2.14 and 0.94 malignant cell equivalents was made for each patient at each DNA input level. Each sample was tested in duplicate for each of four reagent lots resulting in eight results for each of the 66 samples at each dilution condition. A probit approach was used to determine the LoD to be 1.903 malignant cells (95% CI; 1.75 – 2.07) based on the combined data from both DNA inputs (Table 4). The LoQ was defined as the lowest absolute number of malignant cells whose frequency can be quantitatively determined with an accuracy of 70% relative total error. The LoQ was found to be 2.390 malignant cells (95% CI; 1.90 – 9.14) (Table 4).
Table 4: LoD/LoQ by MRD Cell Counts and by MRD Frequency
*Calculated from samples with 500 ng and 20 μg of DNA input.
The clonoSEQ Assay can use a range of DNA inputs from 500 ng to 20 µg of DNA. The LoD/LoQ by MRD frequency will vary based on the DNA input and the total nucleated cells that are evaluated by the assay. The estimated LoD/LoQ at 500 ng and 20 µg of DNA input are shown in Table 4.
To confirm the LoD and LoQ, 1.903 and 2.390 malignant cell equivalents were spiked into 200 ng, 500 ng, 1 μg, 2 μg, 5 μg, 10 μg, 20 μg, and 40 μg of gDNA extracted from bone marrow of healthy subjects. The results showed that the LoD and LoQ of malignant cells detected remained consistent across all DNA input levels.
2.6 Analytical Specificity
2.6.1 Interfering Substances
Testing was performed to characterize the effects of five endogenous (Table 5) and three exogenous (Table 6) substances on the clonoSEQ Assay to identify potential interfering substances.
Table 5: Endogenous Interfering Substances Tested
* Chloroform was used as solvent to resuspend bilirubin (unconjugated) and cholesterol.
Table 6: Exogenous Interfering Substances Tested
* The BMA samples were shipped to Adaptive containing 1.8 mg/ml EDTA (“Low” concentration) for anti-coagulation purposes. Additional EDTA was spiked in to achieve the High level.
† Chloroform inhibition was tested at a single spiked-in volume (2.5µl).
The potential exogenous and endogenous substances were spiked separately into 250 μl aliquots of bone marrow from four different donors. Each condition was replicated for a total of eight times (four donors with two replicates each) and all conditions passed the pre-specified MRD frequency equivalence margin of ± 30%. This study concluded that MRD results were not substantially influenced by the presence of the tested interfering substances.
2.6.2 Cross-Contamination/Sample Carryover
The assessment of cross-contamination included two studies: one study to measure contamination of ID samples during automated DNA extraction of BMA and BMMC and one study to measure contamination of gDNA from MRD samples during PCR, library pooling, and sequencing with the clonoSEQ Assay.
Cross-contamination of ID samples during automated DNA extraction was assessed using a panel of three ALL cancer cell lines and three MM cell lines each spiked to 10% of total cells in a BMA pool of two healthy subjects or a bone marrow mononuclear cell (BMMC) pool of four healthy subjects. PBS (blank) samples were included in this study. Samples were evaluated as to whether they correctly calibrated. There were no false calibrations for run-to-run with 0/44 BMA and 0/44 BMMC false calibrations. There was one false calibration for the well-to-well study with 1/44 BMA and 0/44 BMMC samples falsely calibrating. The falsely calibrated sequence was found in a PBS sample with 83 total templates and the sequence was not associated with any of the six cell lines. The PBS sample provided a sensitive test for contamination since there was no background DNA and a contamination of 83 templates would not be expected to cause false calibration of a clinical specimen.
Cross contamination of incorrectly calling samples MRD positive was assessed using gDNA from peripheral blood from healthy subjects as MRD-negative specimens and blends of cell line gDNA and gDNA from peripheral blood of healthy subjects spiked to a concentration of 5%. The 5% level was used to simulate a patient with clinical relapse. This study evaluated for the presence of a clonal sequence and molecular barcode simultaneously. There were no run-to-run contamination events observed in 0/36 tests. Well-to-well cross contamination was observed in 8/712 comparisons; this was likely caused by contamination of a primer barcode plate sourced from a vendor. All contamination events were below 4×10 -6 . This low level of contamination is unimpactful because tracked clonotype sequences are highly specific to each patient, so contamination between samples from different patients would not affect the reported MRD result. Cross contamination between samples from the same patient is prevented by process controls that disallow co-processing of samples from the same patient.
Linearity of the clonoSEQ Assay using three ALL cell lines (SUP-B15, GM14952, and GM20930) and three MM cell lines (IM9, U266, and L363) was evaluated by blending cell line gDNA with gDNA from healthy subjects using DNA inputs of 200 ng, 2 µg and 20 µg gDNA and tested at zero and across 11 MRD frequencies at each DNA input. This study was performed to measure the linearity of the clonoSEQ Assay at depths beyond the sensitivity of conventional tools. The frequency range of 6.0×10 -5 to 1.0 was tested at the 200 ng DNA input. The frequency range of 6.5×10 -6 to 1.0 was tested at the 2 µg DNA input. The frequency range of 6.6×10 -7 to 0.1 was tested at 20 µg DNA input. The linear range of the assay was determined by finding the input range where the maximum deviation from linearity (based on a quadratic or cubic fit to the data) was less than 5%. Linearity was established for each sample input and disease type tested across the entire tested range (Table 7), with data shown in Figure 4. This study demonstrated linearity of MRD frequencies across several orders of magnitude for each condition tested.
Figure 4: Linearity of the clonoSEQ Assay. Expected (x-axis) and Observed (y-axis) MRD Frequency of Six Cell Lines.
Table 7: Linearity of the clonoSEQ Assay using Cell Lines
Linearity using Clinical Specimens
Linearity was confirmed using clinical samples from the precision study (section 2.4), which evaluated blended gDNA extracted from 23 MM and 21 ALL specimens at three DNA inputs and six MRD frequencies per DNA input. These data were re-analyzed to confirm linearity at the lower frequency range of the assay. The linear range of the assay was determined by finding the input range where the maximum deviation from linearity (based on a quadratic or cubic fit to the data) was less than 5%. Results are summarized in Table 8. The slopes and intercepts are reported as the average and range of values across all clinical specimens that were tested at each DNA input by disease indication. Results from three representative specimens for each ALL and MM are shown in Figure 5. This study demonstrated linearity across a wide range of MRD frequencies for each condition tested using clinical specimens.
Table 8: Linearity of clonoSEQ Assay using Clinical Specimens
Figure 5: Linearity of clonoSEQ Assay. The Expected (x-axis) and Observed (y-axis) MRD Frequency of Six Clinical Samples
2.8 Reagent Stability
2.8.1 In-Use Reagent Stability
An in-use stability study was executed to determine stability needs of the clonoSEQ Assay for reaction mixes and intermediate steps. The following critical steps were evaluated: pre-amp and PCR primer mix stability, master mix stability, complete reaction stability, and process pause stability. gDNA was tested using seven replicates for all conditions tested. Acceptance criteria were based on sequencing results meeting all QC metrics; all of the conditions tested met the pre-specified acceptance criteria and the clonoSEQ Assay in-use stability needs.
2.8.2 Real Time Stability of Pre-Amp and PCR Mixes
The real-time reagent stability studies used the primer QC processes to assess primer performance and determine primer stability. The primer QC process uses a set of synthetic double-stranded molecules representing rearrangements of the targeted exons to determine whether each manufactured lot of pre-amp PCR primers and PCR primers are performing within specification. The priming sites on synthetic molecules are identical to biologic priming sites on targeted exons. Data from these molecules were analyzed and assessed for the ability of the primers to amplify each identified exon at acceptable levels and the presence of primer sequences. These data were used to confirm that the performance of the pre-amp and PCR primers was adequate and consistent with previous primer lots. The performance of the amplification of the synthetic molecules met the pre-specified acceptance criteria.
This real-time reagent stability study established a 12-month shelf life of pre-amp and PCR primer mixes when stored at -20 ± 5° C. These data were confirmed by assessing the equivalence of MRD frequency in 40 clinical samples amplified with primer lots of different ages, and by tracking the stability of MRD measurements of synthetic molecules over time. The conditions tested in the real time stability study met the pre-specified acceptance criteria of a pairwise equivalence test of clinical specimens to be within ± 30% MRD frequency.
2.9.1 Quantitation Accuracy
The analytical quantitation accuracy of the clonoSEQ Assay for MRD testing was assessed relative to multiparametric flow cytometry (mpFC):
- Assessment of the clonoSEQ Assay accuracy in cell mixtures compared to mpFC
- Concordance of the clonoSEQ Assay and mpFC in two clinical validation studies: ALL and MM
- Assessment of the clonoSEQ Assay accuracy in 44 clinical samples
2.9.2 Assessment of clonoSEQ Assay Accuracy in Cell Mixtures Comparing to Multiparametric Flow Cytometry (mpFC)
Accuracy was assessed using cell line blends. Measured MRD frequencies were compared against known frequencies based on diluting cell lines into background mononuclear cells at specific MRD levels. The mpFC lab screened a panel of cancer cell lines and selected 2 MM and 2 ALL cancer cell lines that performed well with mpFC.
This study evaluated two MM cell lines (U266B1 and NCI-H929) and two ALL cell lines (SUP-B15 and GM20390); the mpFC laboratory screened a panel of cancer cell lines and selected these four cell lines based on performance of the mpFC assay. Each cell line was tested at five dilutions from 5×10 -7 to 1×10 -2 . Two replicates of each sample were assessed by the clonoSEQ assay and mpFC. A pairwise comparison of MRD frequency measurements is shown in Figure 6. This study demonstrated similar quantitative accuracy comparing clonoSEQ with mpFC at frequencies above 1×10 -4 .
Figure 6: Pairwise Comparison of MRD Frequency Measurements from mpFC (x-axis) and the clonoSEQ Assay (y-axis)
2.9.3 Concordance with mpFC in Clinical Samples
Two concordance studies between mpFC and the clonoSEQ Assay were performed using clinical samples. For both studies concordance was assessed two ways: concordance of MRD positive or negative calls and concordance of reported MRD frequency. One study used 273 ALL samples from the Children’s Oncology Group (COG) AALL0331 (standard risk) and AALL0232 (high risk) regimens and compared the clonoSEQ Assay to a validated mpFC assay. The other study performed a similar comparison using 91 MM samples from the Dana Farber Cancer Institute (DFCI) Study 10-106 that were measured by both the clonoSEQ Assay and mpFC. MRD negativity was defined as -4 for mpFC in ALL (a commonly used threshold in that patient population) and 3. CLINICAL STUDIES
Clinical validation was demonstrated using an analysis of samples obtained from two previously conducted clinical studies in ALL, one ongoing study in MM and an analysis of a completed study in MM. Samples for the analysis of the clonoSEQ Assay performance in MM were obtained from an ongoing randomized, open label, Phase III Study of a lenalidomide and bortezomib in a combination therapy regimen (DFCI Study 10-106). Multiple timepoints were assessed in this two-arm analysis and not all patients have the same number of MRD assessments (see data in section 3.2). Patients on Arm A (blinded to Adaptive Biotechnologies) had assessments after eight cycles of RVD, and then after lenalidomide maintenance. Patients on Arm B (blinded to Adaptive Biotechnologies) were assessed following three cycles of RVD, following auto transplant and again after two more cycles of RVD consolidation, and then following lenalidomide maintenance.
3.1 Clinical Validation of the clonoSEQ Assay for Acute Lymphoblastic Leukemia in Children’s Oncology Group (COG) Studies AALL0232 and AALL0331
The primary objective of the study was to establish the ability of the clonoSEQ Assay to predict event-free survival (EFS) at the MRD threshold of 10 -4 using available bone marrow samples from patients who were enrolled in previously conducted COG studies AALL0232 and AALL0331. The study was also designed to evaluate the clinical utility of the clonoSEQ Assay using alternative MRD thresholds and continuous MRD measures.
COG study AALL0331 is a Phase III randomized study of different combination chemotherapy regimens in pediatric patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia. COG study AALL0232 is a Phase III randomized study of dexamethasone versus prednisone during induction and high-dose methotrexate with leucovorin rescue versus escalating-dose methotrexate without leucovorin rescue during Interim Maintenance I in patients with newly diagnosed high-risk acute lymphoblastic leukemia. Within these studies, bone marrow was collected at six separate time points to assess response to treatment; however, only the post induction marrow was used for MRD determination.
Clinical samples (pre-treatment BMA and day 29 post-induction BMA) were collected from 619 individuals, with samples from 315 patients who were enrolled as part of the “high risk” COG protocol AALL0232 and samples from 304 patients enrolled as part of the “standard risk” COG protocol AALL0331. Available specimens from these trials were tested with the clonoSEQ assay and results from both studies were pooled into a single analysis. Specimens were selected based on having a sufficient quantity of gDNA, available MRD flow cytometry results and patients with study related endpoints for EFS and overall survival.
A subset of 283 of the 619 patients originally enrolled in COG studies AALL0232 and AALL0331 had leftover samples of sufficient amount that could be tested with the clonoSEQ Assay. The population characteristics between these 283 patients were compared against the remaining 336 that were not tested and there were no significant differences in any characteristic that was evaluated, including age, gender, presence of specific genetic fusions, trisomy, and progression free survival. The 283 bone marrow specimens were tested to evaluate the clinical performance of the clonoSEQ Assay and to demonstrate concordance in MRD measurements between the clonoSEQ Assay and results of original testing with a previous version of the clonoSEQ Assay and mpFC. Ten specimens did not pass QC, leaving results from 273 specimens available for the final analysis.
The clonoSEQ Assay MRD negativity at ≤ 10 -4 was found to predict improved EFS irrespective of age (P=0.0034; Figure 9). Results demonstrate a 2.74-fold higher event risk in MRD positive patients (MRD > 10 -4 ) compared to MRD negative patients (95% CI: 1.330-5.656). Similar findings were published in a broader COG analysis of the relationship between EFS and MRD negativity by an earlier version of the clonoSEQ Assay in pediatric ALL (Wood et al. 2020).
Figure 9: Kaplan-Meier Survival Curve for EFS using the clonoSEQ Assay at an MRD Cutoff of 10 -4 in ALL
Cox regression analysis of MRD and EFS using continuous MRD values demonstrates that the clonoSEQ Assay is significantly associated with EFS after adjusting for age (P=0.0057) and that each 10-fold increase in MRD level is associated with a 1.499-fold increase in event risk (95% CI: 1.139-1.974). These data further demonstrate that the MRD level remains a significant predictor of EFS even after accounting for age, gender, and genetic abnormalities, which demonstrates the utility of MRD measurement in ALL.
Qualitative assessments of MRD were also evaluated with MRD negativity defined as ≤ 10 -5 (Figure 10) is significantly associated with EFS (P=8.4×10 -4 ).
Figure 10: Kaplan-Meier Survival Curve for EFS using the clonoSEQ Assay at an MRD Cutoff of 10 -5 in ALL
The clonoSEQ Assay was used to assess MRD at various disease burden thresholds to determine the correlation of MRD level with EFS. Patients who are clonoSEQ MRD negative (≤10 -5 ) have longer EFS, followed by patients with MRD between 10 -5 and 10 -4 and patients with MRD ≥10 -4 (P=6.5×10 -4 ; Figure 11). These data demonstrate that patients with the lowest levels of MRD have better outcomes than patients with higher disease burden regardless of risk stratification.
Figure 11: Kaplan-Meier Survival Curve for EFS using the clonoSEQ Assay with Three MRD Bins in ALL: ≤10 -5 , 10 -5 – 10 -4 , ≥10 -4 .
These analyses demonstrated that MRD estimation by the clonoSEQ assay is associated with patient outcomes for B-cell precursor ALL.
3.2 Clinical Validation of the clonoSEQ Assay for Multiple Myeloma
Two separate studies were analyzed to support that MRD as estimated with the clonoSEQ Assay is associated with patient outcomes in MM, including the DFCI Study 10-106 and the ALCYONE study.
The objective of this study was to establish that the clonoSEQ Assay is predictive of progression-free survival (PFS) and disease-free survival (DFS) in MM. Patient samples were accrued under DFCI Study 10-106, “A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.”
A subset of 365 of the 720 patients originally enrolled in DFCI Study 10-106 had leftover samples of sufficient amount to be tested with the clonoSEQ Assay. The population characteristics between these 365 patients were compared against the remaining 355 patients that were not tested and there were no significant differences in any characteristic that was evaluated, including age, gender, ISS staging, cytogenetic status and progression free survival. Samples from 365 patients were tested and results from 323 patients were evaluable and passed QC. Seventy-five of the samples were available from patients in complete response (CR) at the time of first MRD assessment. This study aimed to demonstrate the association of the first MRD measurement with DFS in patients who achieved CR and with PFS in all evaluable patients.
Samples from 75 patients who had achieved CR were evaluable for analysis. Continuous clonoSEQ MRD levels were modestly associated with DFS in patients who have achieved CR (P=0.064) such that patient with lower MRD levels were less likely to progress.
The ability of the clonoSEQ Assay MRD measurements to predict PFS in all 323 evaluable patients was also assessed. clonoSEQ measurements demonstrated that MRD status at a threshold of 10 -5 significantly predicts PFS in all patients (P= 0.027, Figure 12).
Figure 12: Kaplan-Meier Survival Curve for PFS using the clonoSEQ Assay at an MRD cutoff of 10 -5 in MM
Cox regression analysis using a continuous measure of MRD was also associated with disease progression (P=1.9×10 -7 ). For every 10-fold increase in continuous clonoSEQ MRD measurement, the likelihood of an event is 1.69 times higher (95% CI:1.071-2.67).
The ALCYONE Trial was a multicenter, randomized, open-label, active-controlled phase 3 trial that evaluated daratumumab plus bortezomib, melphalan and prednisone (D-VMP) versus bortezomib, melphalan and prednisone (VMP) in 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. The result of this study was reported in (Mateos et al. 2020).
Within this trial, MRD was assessed by the clonoSEQ Assay using of BMA collected at screening, at the time of confirmation of complete response or stringent complete response, and at 12, 18, 24, and 30 months after the first dose in patients having a complete response or stringent complete response. Patients who did not achieve a CR were considered to be MRD positive. An MRD threshold of 10 -5 was used for analysis.
Regardless of treatment group, patients who were MRD negative by the clonoSEQ Assay at ≤10 -5 had longer PFS compared to MRD positive patients (Figure 13). In patients with persistent MRD, PFS was longer in the daratumumab group than in the control group.
Figure 13: Analysis of MRD with Progression-Free Survival. Patients who were MRD negative by the clonoSEQ Assay had longer PFS compared to MRD positive patients.
In summary, MRD negativity as measured by the clonoSEQ Assay was associated with improved patient outcomes in studies of ALL and MM. These data support the use of the clonoSEQ Assay to measure MRD and to be used for monitoring MRD in patients diagnosed with ALL and MM, to monitor changes in burden of disease during and after treatment.
In summary, the MRD negativity as measured by the clonoSEQ assay was associated with improved patient outcomes in studies of ALL and MM. These data support the use of clonoSEQ to assess MRD and monitor residual disease in patients diagnosed with ALL and MM, in order to track changes in burden of disease during and after treatment. In samples from patients diagnosed with ALL and MM, the clonoSEQ Assay provides robust quantitative measurements of MRD frequencies from 10 -6 – 10 -4 , with sensitivity increasing in proportion to the amount of input material. Clinical outcomes are strongly associated with MRD levels measured by the assay for the purposes of detecting and monitoring residual disease in patients diagnosed with ALL and MM, in accordance with clinical guidelines.
1. Borowitz M.J., et.al., Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2020 Aug 20;126(8):964-71.
2. Mateos M.V., et.al., for the ALCYONE Trial Investigators, Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine. 2020 Feb 8;378(6):518-528.
3. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1. 2020.
4. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 1.2020.
5. Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment with SCT in MM Patients up to Age 65 (DFCI Study 10-106), NCT01208662
6. Wood B, et.al., Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2020 Mar 22;131(12):1350-1359.
6. SPECIMEN AND SHIPPING INSTRUCTIONS
The final version of this assignment should have two parts:
Part One: Shot By Shot Outline – 20 points
In this part, you provide a detailed technical description of the sequence, emphasizing the cinematography, mise-en-scene, and soundtrack or lighting elements.
Part Two: Analysis – 50 points
In this part, you summarize 2-3 important cinematic techniques/parts of the mise-en-scene and analyze/evaluate/explain their contribution to the viewers understanding of the sequence and/or the overall narrative.
Process – Suggestions for prewriting and preparation for the assignment:
1. Choose which of the movies we have seen in class that you wish to to use. View the movie again, and select a sequence of shots you think uses several significant and important cinematic techniques that enhance the narrative of the film and the film’s ability to suture the audience. A sequence is not necessarily an entire scene. I want you to focus on 8-12 shots.
2. Take extensive notes on the 8-12 shots you selected by repeatedly viewing them until you have recorded all the important information.
3. Observe and take notes on all of the important cinematic techniques used in the sequence:
Order of the shots
Camera Work – movement, angle, framing
Movement of the actors (NOT dialogue)
Other mise-en-scene elements not mentioned above
4. Write the shot by shot outline. After you have collected your ideas, type a shot by shot outline using the format of the sample below. This part has to be accurate and precise, and your comments have to be detailed and careful. You can think of it as an outline of the main visual structure of the sequence. This shot by shot outline is worth 25 points.
5. Prepare to write your analysis,
Think about the importance and impact of the technical structures you have identified.
What do you notice when you think about the visual style or specific shot-by-shot treatment of the sequence? Does the sequence have a lot of close-ups? No close-ups? A change in lighting? A change in style? What new elements emerge that you would not have noticed otherwise?
6. Write two short paragraphs, minimum of 150 words each, that discuss the importance and impact of the technical structure used in the sequence. Each paragraph must use a minimum of four different cinematic terms effectively in a way that both shows that you understand the term and that you understand its meaning/use. Please BOLD where you have used such terms.
Sample Sequence Analysis
-This sample is for the movie Psycho.
You need to analyze a sequence from any of the movies we have seen so far this semester.
Sequence – Marion preparing to pack – 2 minutes
LITE 216 – online
526 words in my analysis
Part One: Shot by Shot Outline
[This sample is just a start… It is provided so you can see the depth that I expect.]
Shot 1: A. Medium long shot of Marion framed in front of the closet, wearing her bra and slip. (Note: Similar outfit as in her hotel encounter with Sam, although that was white.). She looks towards frame right, then looks back to the back of the frame towards the closet.
B. Camera tilts down, zooms in to extreme close up of the money on the bed, implicitly creating eyeline match with what she had looked at in part A.
C. Camera zooms out, pans left following contour of the bed and tilts up to focus on suitcase in close up. Camera stays unmoving on suitcase for 3 seconds.
Shot 2. Cut to Marion medium shot in front of closet again. She is getting dressed. She looks again towards the bed as she continues to dress and looks back down to her clothes.
Shot 3. Cut to close up of envelope on the bed. This close up is framed so that the envelope is at the center of the frame, and it is a closer shot than in previous shot.
Shot 4. Cut back to Marion in medium close up (head and shoulders) as she buttons up her shirt. Camera moves with her as she moves around, as if to have her always in the middle of the frame. She leans towards frame left (putting on her shoes?).
Shot 5. Cut to close up of her arm arranging things in the suitcase. Camera stays on suitcase, and does not move.
Shot 6. A. Cut back to Marion, same framing as in Shot 4 (she is in the middle of the frame, and the camera moves with her to keep her in the middle). Interestingly, behind her we see the shower of her room: the showerhead and curtain are clearly visible behind her. On the wall on the other side there is a picture (looks like a photo of a little girl).
B. Marion looks towards frame left, and starts moving. Camera pans around the room, still keeping her in center. Pan left to mirror. She looks at herself (eye to eye) while arranging her clothes, then looks down at her blouse. She looks over her right shoulder towards bottom frame right (the bed).
Shot 7. Cut to medium long shot of the money on the bed. Bed seems to take over the whole frame.
Shot 8. Cut back to Marion as she folds her clothes. She is at frame left (not at center).
[And so on: this can continue for as long as you feel is important for you to make the claim you need].
Part Two: Analysis – 50 points (25 points per paragraph)
[Below are basic ideas of how you could discuss your sequence. Do not copy from this sample. Your individual paragraphs will probably be LONGER.] – In each paragraph, you MUST use a minimum of 4 cinematic terms in a way that both shows that you understand the term and that you understand its meaning/use. Please BOLD where you have used such terms.
Camera Work and Sound: This sequence has consistent styling: it uses medium longs shots (showing Marion in the room) and close ups (tight shot of a specific prop), pans (camera moving on the horizontal axis) and some canted shots (camera at a slight angle with regard to the horizontal axis). The camera work seems motivated by the relationship between Marion and the objects around her. For example, the camera frames her in the middle and follows her motions (pan), but in contrast it stops and freezes on the objects without any pans. Even though for most the sequence the pans are motivated by her gaze, the beginning of the sequence is camera-motivated, as if to establish the three poles of the communication in the scene, Marion, the money and the suitcase. The slightly canted shots give a preview of the chaos to come, but the angle is slight and the foreshadowing is minimal. There is no dialogue, but there is a contrast between silence and soft music, which is non-diegetic sound because the sound is not emanating from the action within the scene. There appears to be a relationship between the types of shot and the types of sound. During the moving pans the music is softer and during the stationary close-ups the music is silent. This lead viewers to concentrate more on the close up image because there are no distracting sounds. In fact the absence of sound emphasizes the importance of what is on the screen.
Props: There are several items of the mise-en-scene that the viewer still needs to determine if they will be important for the narrative. The camera emphasizes the prop of the suitcase, and this makes sense because at this point in the plot, the theft represented by the suitcase is what is creating the tension in the narrative. The shower (curtain and shower head) are also part of the frame in one of the shots. Because the camera pans and follows Marion’s motions in an enclosed space, this scene feels similar to the scenes at Bates Motel, which it seems to directly pre-figure. The visible shower in the background is uncanny, I did not notice it the first time I saw this scene, but the shower is part of the frame in most of the shots that show Marion getting dressed. This seems insignificant, but the viewer will come to know that the shower is important with the suitcase is not. This switching of the symbols in the scene will later contribute to the viewer’s surprise when Marion is murdered and the tension of the narrative totally switches. The envelope is shown in close up. This is perhaps representative of Marion’s obligations to Sam or it could symbolize her opportunity to be free.
You will be evaluated on the following criteria:
- Depth will evaluate your ability to identify significant cinematic elements in the sequence
- Insight will evaluate your ability to analyze the meanings of the significant elements in the sequence
- Terminology will evaluate your ability to use four cinematic terms effectively
- Style/Format will evaluate your writing style, with an emphasis on clarity, organization entertainment value
- Outline will evaluate your ability to accurately outline the sequence
This will be the rubric for EACH of the analysis paragraphs
Best Binary Options Broker 2020!
Perfect For Beginners!
Free Demo Account!
Free Trading Education!
Get Your Sign-Up Bonus Now!
Good Choice For Experienced Traders! 2nd place in the ranking!